In principle, CRP reduction could bring therapeutic benefits in a multitude of acute and chronic diseases.

PentraSorb® CRP is a potential therapeutic option for

If you would like to participate in one or more of the listed studies or start a new study, please Contact us.

* The "CRP Apheresis in STEMI" trial is an investigator-initiated trial in which the following hospitals are already recruiting:

    • University Clinic of Innsbruck, Austria
      Principal Investigator: Sebastian J Reinstadler, MD, PhD
    • Leipzig Heart Center, Germany
      Principal Investigator: Holger Thiele, MD